Mersana stockholders approve reverse stock split at 2025 annual meeting

Mersana Therapeutics, Inc.

Three Class II directors elected: Allene M. Diaz, Andrew A.F. Hack, Kristen M. Hege.
Advisory vote on executive compensation approved with 63.6M for and 1.1M against.
Ratification of Ernst & Young as auditor for FY2025 approved overwhelmingly.
Reverse stock split proposal approved: ratio of 1-for-2 to 1-for-25, timing at Board's discretion.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.